Q3 Earnings Forecast for CalciMedica Issued By HC Wainwright

CalciMedica Inc. (NASDAQ:CALC) – Equities research analysts at HC Wainwright increased their Q3 2026 EPS estimates for CalciMedica in a research note issued to investors on Wednesday, August 12th. HC Wainwright analyst J. Pantginis now anticipates that the company will post earnings per share of ($0.15) for the quarter, up from their previous estimate of ($0.36). HC Wainwright has a “Neutral” rating on the stock. The consensus estimate for CalciMedica’s current full-year earnings is ($1.35) per share. HC Wainwright also issued estimates for CalciMedica’s Q4 2026 earnings at ($0.17) EPS, FY2026 earnings at ($1.05) EPS, FY2027 earnings at ($0.63) EPS and FY2028 earnings at ($0.71) EPS.

CalciMedica (NASDAQ:CALC) last issued its quarterly earnings data on Tuesday, August 11th. The company reported ($0.45) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.17).

A number of other equities analysts have also commented on the company. Weiss Ratings raised CalciMedica from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday, July 29th. UBS Group reiterated a “neutral” rating on shares of CalciMedica in a research report on Thursday. One research analyst has rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $10.00.

CalciMedica Stock Performance

Shares of CALC stock opened at $0.66 on Friday. CalciMedica has a 52-week low of $0.46 and a 52-week high of $7.20. The firm has a market capitalization of $10.39 million, a PE ratio of -0.48 and a beta of 0.91. The stock has a fifty day simple moving average of $0.81 and a two-hundred day simple moving average of $0.78.

Insiders Place Their Bets

In other CalciMedica news, Director Fred A. Middleton purchased 248,972 shares of the company’s stock in a transaction dated Thursday, June 25th. The shares were acquired at an average price of $0.80 per share, for a total transaction of $199,177.60. Following the completion of the purchase, the director owned 1,063,272 shares of the company’s stock, valued at approximately $850,617.60. The trade was a 30.57% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through the SEC website. 28.25% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On CalciMedica

A number of institutional investors and hedge funds have recently modified their holdings of the company. Renaissance Technologies LLC lifted its holdings in shares of CalciMedica by 45.0% in the 1st quarter. Renaissance Technologies LLC now owns 128,075 shares of the company’s stock valued at $69,000 after buying an additional 39,775 shares during the period. 180 Wealth Advisors LLC increased its holdings in shares of CalciMedica by 297.2% during the 1st quarter. 180 Wealth Advisors LLC now owns 126,500 shares of the company’s stock valued at $68,000 after purchasing an additional 94,650 shares in the last quarter. Boothbay Fund Management LLC purchased a new stake in CalciMedica during the fourth quarter worth $506,000. Jane Street Group LLC purchased a new position in CalciMedica in the fourth quarter valued at $127,000. Finally, PVG Asset Management Corp purchased a new stake in shares of CalciMedica during the 4th quarter worth about $302,000.

CalciMedica Company Profile

CalciMedica, Inc (NASDAQ:CALC) is a clinical-stage biopharmaceutical company focused on developing therapies that modulate calcium-mediated inflammatory pathways. Headquartered in Northbrook, Illinois, the company applies proprietary ion channel technology to address severe inflammatory disorders driven by dysregulated immune responses.

The company’s lead product candidate, Auxora™, is a selective inhibitor of calcium release-activated calcium (CRAC) channels. Auxora is being evaluated in clinical trials for the treatment of acute pancreatitis associated with systemic inflammatory response syndrome (SIRS) and acute respiratory distress syndrome (ARDS) in patients with severe pulmonary conditions, including COVID-19 pneumonia.